(19)
(11) EP 4 680 610 A1

(12)

(43) Date of publication:
21.01.2026 Bulletin 2026/04

(21) Application number: 24709436.0

(22) Date of filing: 11.03.2024
(51) International Patent Classification (IPC): 
C07D 498/04(2006.01)
A61K 31/5383(2006.01)
A61P 5/24(2006.01)
(52) Cooperative Patent Classification (CPC):
C07D 498/04; A61P 5/24
(86) International application number:
PCT/EP2024/056351
(87) International publication number:
WO 2024/188935 (19.09.2024 Gazette 2024/38)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 16.03.2023 EP 23162389

(71) Applicant: Bayer Consumer Care AG
4052 Basel (CH)

(72) Inventors:
  • ROTTMANN, Antje
    13089 Berlin (DE)
  • PETERS, Michaele
    10405 Berlin (DE)
  • ENGELEN, Anna
    45149 Essen (DE)
  • BORDINI, Ellenia
    37135 Verona (IT)
  • DAVALLI, Silvia
    37135 Verona (IT)
  • CUFARI, Domenico
    37135 Verona (IT)
  • TROWER, Mike
    Stevenage Herts SG1 2FX (GB)

(74) Representative: BIP Patents 
c/o Bayer Intellectual Property GmbH Alfred-Nobel-Straße 50
40789 Monheim am Rhein
40789 Monheim am Rhein (DE)

   


(54) NOVEL DUAL NK-1/NK-3 RECEPTOR ANTAGONISTS